Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Mood disorders and serotonin transporter density in ecstasy users--the influence of long-term abstention, dose, and gender.

de Win MM, Reneman L, Reitsma JB, den Heeten GJ, Booij J, van den Brink W.

Psychopharmacology (Berl). 2004 May;173(3-4):376-82. Epub 2004 Jan 15.

PMID:
14726997
2.

Effects of dose, sex, and long-term abstention from use on toxic effects of MDMA (ecstasy) on brain serotonin neurons.

Reneman L, Booij J, de Bruin K, Reitsma JB, de Wolff FA, Gunning WB, den Heeten GJ, van den Brink W.

Lancet. 2001 Dec 1;358(9296):1864-9.

PMID:
11741626
3.

A voxel-based PET investigation of the long-term effects of "Ecstasy" consumption on brain serotonin transporters.

Buchert R, Thomasius R, Wilke F, Petersen K, Nebeling B, Obrocki J, Schulze O, Schmidt U, Clausen M.

Am J Psychiatry. 2004 Jul;161(7):1181-9.

PMID:
15229049
4.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users.

Thomasius R, Petersen K, Buchert R, Andresen B, Zapletalova P, Wartberg L, Nebeling B, Schmoldt A.

Psychopharmacology (Berl). 2003 Apr;167(1):85-96. Epub 2003 Mar 11.

PMID:
12632248
5.

Cortical serotonin transporter density and verbal memory in individuals who stopped using 3,4-methylenedioxymethamphetamine (MDMA or "ecstasy"): preliminary findings.

Reneman L, Lavalaye J, Schmand B, de Wolff FA, van den Brink W, den Heeten GJ, Booij J.

Arch Gen Psychiatry. 2001 Oct;58(10):901-6.

PMID:
11576026
6.

Reduced in vivo binding to the serotonin transporter in the cerebral cortex of MDMA ('ecstasy') users.

Semple DM, Ebmeier KP, Glabus MF, O'Carroll RE, Johnstone EC.

Br J Psychiatry. 1999 Jul;175:63-9.

PMID:
10621770
7.

Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective.

Thomasius R, Zapletalova P, Petersen K, Buchert R, Andresen B, Wartberg L, Nebeling B, Schmoldt A.

J Psychopharmacol. 2006 Mar;20(2):211-25. Review.

PMID:
16510479
8.

Long-term effects of "ecstasy" use on serotonin transporters of the brain investigated by PET.

Buchert R, Thomasius R, Nebeling B, Petersen K, Obrocki J, Jenicke L, Wilke F, Wartberg L, Zapletalova P, Clausen M.

J Nucl Med. 2003 Mar;44(3):375-84.

9.

Relationship between ecstasy use and depression: a study controlling for poly-drug use.

Roiser JP, Sahakian BJ.

Psychopharmacology (Berl). 2004 May;173(3-4):411-7. Epub 2003 Dec 3.

10.

Use of amphetamine by recreational users of ecstasy (MDMA) is associated with reduced striatal dopamine transporter densities: a [123I]beta-CIT SPECT study--preliminary report.

Reneman L, Booij J, Lavalaye J, de Bruin K, Reitsma JB, Gunning B, den Heeten GJ, van Den Brink W.

Psychopharmacology (Berl). 2002 Jan;159(3):335-40. Epub 2001 Nov 20.

PMID:
11862367
11.

Quantitative PET studies of the serotonin transporter in MDMA users and controls using [11C]McN5652 and [11C]DASB.

McCann UD, Szabo Z, Seckin E, Rosenblatt P, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Neuropsychopharmacology. 2005 Sep;30(9):1741-50.

12.

Effects of MDMA (ecstasy) use and abstention on serotonin neurons.

Ratzenböck E.

Lancet. 2002 May 4;359(9317):1617; author reply 1617-8. No abstract available.

PMID:
12047990
13.

Effects of MDMA (ecstasy) use and abstention on serotonin neurons.

Haddad PM, Strickland P, Anderson I, Deakin JF, Dursun SM.

Lancet. 2002 May 4;359(9317):1616-7; author reply 1617-8. No abstract available.

PMID:
12047989
14.

The effects of ecstasy on neurotransmitter systems: a review on the findings of molecular imaging studies.

Vegting Y, Reneman L, Booij J.

Psychopharmacology (Berl). 2016 Oct;233(19-20):3473-501. doi: 10.1007/s00213-016-4396-5. Epub 2016 Aug 28. Review.

15.

Recreational ecstasy use and depression.

Guillot C, Greenway D.

J Psychopharmacol. 2006 May;20(3):411-6.

PMID:
16574715
16.

Decreased cerebral cortical serotonin transporter binding in ecstasy users: a positron emission tomography/[(11)C]DASB and structural brain imaging study.

Kish SJ, Lerch J, Furukawa Y, Tong J, McCluskey T, Wilkins D, Houle S, Meyer J, Mundo E, Wilson AA, Rusjan PM, Saint-Cyr JA, Guttman M, Collins DL, Shapiro C, Warsh JJ, Boileau I.

Brain. 2010 Jun;133(Pt 6):1779-97. doi: 10.1093/brain/awq103. Epub 2010 May 17.

17.

Memory function and serotonin transporter promoter gene polymorphism in ecstasy (MDMA) users.

Reneman L, Schilt T, de Win MM, Booij J, Schmand B, van den Brink W, Bakker O.

J Psychopharmacol. 2006 May;20(3):389-99.

PMID:
16574713
18.

Mapping serotonergic dysfunction in MDMA (ecstasy) users using pharmacological MRI.

Schouw ML, Gevers S, Caan MW, Majoie CB, Booij J, Nederveen AJ, Reneman L.

Eur Neuropsychopharmacol. 2012 Aug;22(8):537-45. doi: 10.1016/j.euroneuro.2011.12.002. Epub 2011 Dec 29.

19.

Positron emission tomographic studies of brain dopamine and serotonin transporters in abstinent (+/-)3,4-methylenedioxymethamphetamine ("ecstasy") users: relationship to cognitive performance.

McCann UD, Szabo Z, Vranesic M, Palermo M, Mathews WB, Ravert HT, Dannals RF, Ricaurte GA.

Psychopharmacology (Berl). 2008 Oct;200(3):439-50. doi: 10.1007/s00213-008-1218-4. Epub 2008 Jul 27.

20.

Is recreational ecstasy (MDMA) use associated with higher levels of depressive symptoms?

Guillot C.

J Psychoactive Drugs. 2007 Mar;39(1):31-9. Review.

PMID:
17523583

Supplemental Content

Support Center